Evolus, Inc.

Evolus, Inc.

EOLSNYSE / NASDAQHealthcareSmall cap

$6.52-$0.48 (-6.9%)

Last close · Data as of Nov 20, 2026

Market cap
$434.6M
P/E
-8.4x
EV / EBITDA
-23.8x
Revenue
$297.2M
Net margin
-17.4%
ROCE
-25.0%

-1.5% over the last year

Evolus, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-11.5%
3M
-21.9%
6M
-1.1%
1Y
-1.5%
5Y
+2.2%

52-week range

Day change -$0.48 (-6.9%) from $7.00 to $6.52 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in EOLS, bought on each weekday since 2021.

News & filings

What Evolus filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths

No strength stands out for this company on the data on file.

  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Sector
Healthcare
Shares outstanding
65.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$434.6M
P/E
-8.4x
P/B
-18.8x
EV / EBITDA
-23.8x
EV / Sales
1.8x
P/S
1.5x
52-week high
$9.30
52-week low
$3.94

Profitability

Operating margin
-12.7%
Net margin
-17.4%
EBITDA margin
-7.6%
ROE
223.5%
ROCE
-25.0%
ROIC
-31.6%
ROA
-22.9%
Asset turnover
1.32

Growth

Revenue
$297.2M
Revenue growth, 1Y
11.6%
Revenue CAGR, 3Y
26.0%
Net profit growth, 1Y
2.4%
Free cash flow
-$50.7M

Solvency

Current ratio
1.90
Debt / Equity
-6.71
Debt / Assets
0.69
CFO / Net profit
0.82
Cash / Market cap
12.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$297.2M
Cost of revenue$100.1M
Gross profit$197.1M
Operating expenses$234.7M
Research and development$9.6M
Selling, general and administrative$220.8M
Operating income-$37.6M
Interest and other-$13.4M
Pretax income-$51.0M
Tax and other$680.0k
Net income-$51.6M

Revenue and net profit

Revenue grew 11.6% in FY2025; net profit is the dashed line.

Evolus, Inc. revenue and net profit by fiscal year
Evolus, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$148.6M-$74.4M
FY2023$202.1M-$61.7M
FY2024$266.3M-$50.4M
FY2025$297.2M-$51.6M

Cash flows

FY2025: -$42.3M from operations, -$50.7M free after investment (dashed).

Evolus, Inc. operating and free cash flow by fiscal year
Evolus, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$84.9M-$87.9M
FY2023-$34.0M-$35.6M
FY2024-$18.0M-$22.8M
FY2025-$42.3M-$50.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$297.2M+11.6%1Y
EBITDA
-$22.5M
Net profit
-$51.6M
Cash from operations
-$42.3M
Free cash flow
-$50.7M
Revenue CAGR, 3Y
26.0%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$297.2M-$22.5M-$51.6M-$50.7M223.5%+11.6%+2.4%

Monthly returns

Month-by-month returns of EOLS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$225.9M
Liabilities$249.0M
Equity-$23.1M
Paid-in capital$638.1M
Retained earnings-$661.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; EOLS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Evolus, Inc. (this company)1.8x

Not shown (no positive earnings and no EV / Sales): Rezolute, Inc., Neurogene Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Evolus, Inc.EOLSthis company$434.6M-8.4x-18.8x223.5%-23.8x
NRC HealthNRC$445.1M38.4x31.8x82.9%17.2x
Myriad Genetics, Inc.MYGN$443.0M-1.2x1.2x-99.4%-1.5x
Varex Imaging CorporationVREX$440.9M—0.9x-14.9%973.8x
Emergent BioSolutions Inc.EBS$435.5M8.3x0.8x10.1%3.4x
Rezolute, Inc.RZLT$434.3M-5.8x2.7x-45.9%-4.3x
Neurogene Inc.NGNE$434.2M-4.8x1.6x-34.1%-3.9x
ClearPoint Neuro, Inc.CLPT$429.5M-16.8x15.3x-91.1%-21.2x
Orthofix Medical Inc.OFIX$418.0M-4.5x0.9x-20.5%51.8x
Peer median—-4.5x1.4x-27.3%0.9x

Year-to-date ROI

EOLS since 1 January, against earlier years.

Historical volatility

EOLS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Evolus, Inc. operating margin by fiscal year
Evolus, Inc. operating margin by fiscal year
DateOperating margin
FY2022-40.1%
FY2023-22.3%
FY2024-10.2%
FY2025-12.7%
LineFY2025
Cost of revenueCost Of Revenue$100.1M
Gross profitGross Profit$197.1M
Operating expensesOperating Expense$234.7M
Research and developmentResearch And Development$9.6M
Selling, general and administrativeSelling General And Administration$220.8M
Depreciation and amortisationDepreciation And Amortization In Income Statement$4.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$4.3M
Total expensesTotal Expenses$334.8M
Pretax incomePretax Income-$51.0M

Learn while you research

Academy chapters picked for Evolus, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →